« Previous
Next »
Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4
, Pages
391-399
, July 2009
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
To access this article, please choose from the options below
PII: S1078-1439(08)00069-0
doi: 10.1016/j.urolonc.2008.03.017
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4
, Pages
391-399
, July 2009
